Can B Corp. Enhances Cannabis Patent Monetization Strategy with Fox Rothschild Partnership

Can B Corp. (OTCQB:CANB), through its subsidiary Nascent Pharma Holdings, Inc., has taken a significant step towards monetizing its cannabis patent portfolios by retaining Fox Rothschild, a prominent U.S. law firm. This move underscores the company's strategic focus on leveraging its intellectual property within the burgeoning cannabis and psychedelic industries. James Smedley, a Partner at Fox Rothschild, will spearhead the efforts to maximize the value of Nascent Pharma's two cannabis patents, which were independently valued at $122 million in December 2020, with potential global valuation reaching up to $750 million when considering the THC and CBD markets.

The patents in question have already demonstrated their resilience by surviving an invalidity challenge in Federal Court, affirming their validity and the innovative nature of the formulations they cover. These patents pertain to the extraction of pharmaceutically active components from cannabis, specifically targeting formulations where cannabinoids such as CBD, THC, and others constitute more than 95% of the composition. This technology has wide-ranging applications, including beverages, tinctures, vape pen liquids, and liquid-filled capsules, covering a substantial segment of the hemp and cannabis industry.

Moreover, the method-of-use patent associated with these formulations opens new avenues for managing various debilitating conditions, including cancer, chronic pain, and opioid dependencies, highlighting the potential health benefits and therapeutic applications of cannabis-derived products. The collaboration with Fox Rothschild is poised to enhance Can B Corp.'s ability to capitalize on these patents, not only in the U.S. but also in foreign markets where the patents have been granted.

This development is a testament to the growing economic impact and legitimacy of the cannabis and psychedelic industries, as companies like Can B Corp. navigate the complex legal and financial landscapes to bring innovative solutions to market. The strategic monetization of these patents could set a precedent for how intellectual property is leveraged in this emerging sector, offering insights into the potential for significant financial and therapeutic advancements.